Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
New approach to genomic testing identifies women at low risk of recurrence
January 6th, 2005
An initial validation study presented by Exagen Diagnostics researchers at the San Antonio Breast Cancer Symposium suggests it may soon be possible to distinguish good prognosis from poor prognosis in any newly-diagnosed breast cancer patient based on DNA changes in the patient's tumor. Those patients identified as having a very good prognosis may do well without chemotherapy or hormonal therapy after their tumors have been removed. In a retrospective study of 308 patients conducted with the University of New Mexico Cancer Research and Treatment Center at the Health Sciences Center, Exagen Diagnostics reported the discovery of two, 3-gene sets of...
Source: Women's Health Weekly (2005-01-06)
|
